Swainsonine

Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity[1][2][3].

Product Specifications

CAS Number

[72741-87-8]

Product Name Alternative

Tridolgosir

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/swainsonine.html

Purity

99.9

Solubility

H2O : 4.17 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H](O)CN2CCC[C@@H](O)[C@]12[H]

Molecular Formula

C8H15NO3

Molecular Weight

173.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Dorling PR, et al. Inhibition of lysosomal alpha-mannosidase by swainsonine, an indolizidine alkaloid isolated from Swainsona canescens. Biochem J. 1980 Nov 1;191 (2) :649-51.|[2]Sun L, et al. Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression. BMC Cancer. 2019 Mar 19;19 (1) :247. doi: 10.1186/s12885-019-5425-7.|[3]Santos FM, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine. 2011 Sep 15;18 (12) :1096-101.